Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FLVCR choline and heme transporter 1 (FLVCR1)
- Target
- FLVCR1
- Molecular classification
- Transporter, member of the major facilitator superfamily, specifically a heme and choline transporter
01
Overview
FLVCR1 encodes a high-affinity, multi-transmembrane transporter protein in the major facilitator superfamily, responsible for cellular export of heme and the import of choline and ethanolamine. It is crucial for regulating intracellular heme concentration and preventing toxicity, as well as for providing substrates for phospholipid biosynthesis through the Kennedy pathway. Functional impairment leads to severe neurodegenerative disorders (posterior column ataxia with retinitis pigmentosa), congenital anemias, and metabolic syndromes. FLVCR1 is considered a therapeutic target and a biomarker for several hereditary and acquired diseases
- Other names
- SLC49A1FLVCRMFSD7BPCAAXPC1Feline leukemia virus subgroup C cellular receptor 1FLVCR heme transporter 1ataxia, posterior column 1, with retinitis pigmentosa
02
Mechanism of action
Drugs or compounds targeting FLVCR1 are expected to modulate heme and/or choline transport, impacting cellular iron metabolism, erythropoiesis, and phospholipid synthesis; specific mechanisms depend on molecular binding and possible inhibition or facilitation of transport
03
Biological functions
Heme transportcholine and ethanolamine transportcellular iron homeostasisprotection against heme toxicityinvolvement in phospholipid biosynthesis via the Kennedy pathwayerythropoiesis
04
Disease associations
Cancerneurodegenerative disease (posterior column ataxia with retinitis pigmentosa)hematological disorder (Diamond-Blackfan syndrome)skeletal/craniofacial phenotypes
05
Safety considerations
Targeting FLVCR1 may pose risks of disrupting heme homeostasis, causing hematologic (anemia) and neurodegenerative phenotypesLoss-of-function mutations cause disease, so inhibition may have substantial on-target toxicity and adverse effects
06
Biomarkers
Mutations or expression changes in FLVCR1 have been considered as biomarkers in posterior column ataxia with retinitis pigmentosa and Diamond-Blackfan syndromeother heme-related biomarkers may be researched
Beyond the preview
Go deeper on FLVCR choline and heme transporter 1 (FLVCR1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FLVCR choline and heme transporter 1 (FLVCR1).